TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34889650

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 748

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 748
Study: 34378472

Group type: EXPERIMENTAL
Intervention: Loss-framed text messages
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Gain-framed text messages
Number of subjects: 536
Study: 34364196

Group type: EXPERIMENTAL
Intervention: Women who experienced IPV
Number of subjects: 1788

Group type: COMPARATOR
Intervention: Women who did not experience IPV
Number of subjects: 1788
Study: 32156204

Group type: EXPERIMENTAL
Intervention: Dynamic blood pressure parameters (BP variability)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Steady blood pressure parameter (hypotension time with mean arterial pressure <90 mm Hg)
Number of subjects: 381
Study: 34626672

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 32823886

Group type: EXPERIMENTAL
Intervention: High Polyphenol Diet (HPD)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Low Polyphenol Diet (LPD)
Number of subjects: 99
Study: 36576555

Group type: EXPERIMENTAL
Intervention: Diclofenac-Orphenadrine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (Isotonic saline solution)
Number of subjects: 72
Study: 34328848

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 detection incidental to hospitalization
Number of subjects: 346
Study: 32329092

Group type: EXPERIMENTAL
Intervention: Pregabalin plus opioids
Number of subjects: 46

Group type: COMPARATOR
Intervention: Opioids alone
Number of subjects: 46
Study: 36775514

Group type: EXPERIMENTAL
Intervention: Concurrent training (CT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No training (Control group)
Number of subjects: 31
Study: 34435694

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied once daily (QD)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily (BID)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2% (both QD and BID)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 81
Study: 32434370

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 60
Study: 35908682

Group type: EXPERIMENTAL
Intervention: Mechanical instrumentation with adjunct photodynamic therapy (PDT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Mechanical instrumentation without adjunct photodynamic therapy (Control)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Mechanical instrumentation without adjunct photodynamic therapy (Control) in Group 2
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mechanical instrumentation with adjunct photodynamic therapy (PDT) in Group 2
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mechanical instrumentation with adjunct photodynamic therapy (PDT) in Group 1
Number of subjects: 107

Group type: COMPARATOR
Intervention: Mechanical instrumentation without adjunct photodynamic therapy (Control) in Group 1
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mechanical instrumentation with or without PDT
Number of subjects: 107

Group type: COMPARATOR
Intervention: Healthy patients (Group 3)
Number of subjects: 107
Study: 32145440

Group type: EXPERIMENTAL
Intervention: Granulocyte‐Macrophage Colony Stimulating Factor (GM‐CSF) 500 μg/day subcutaneously thrice weekly for three weeks, followed by a second administration after 3 months.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo injections thrice weekly for three weeks, followed by matching placebo injections after 3 months.
Number of subjects: 176
Study: 35361012

Group type: EXPERIMENTAL
Intervention: Participants who read any type of comment posted by other users
Number of subjects: 296

Group type: COMPARATOR
Intervention: Participants who only viewed brelfies
Number of subjects: 296
Study: 32552264

Group type: EXPERIMENTAL
Intervention: Extended-release oral milrinone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 32838463

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo injection (PI)
Number of subjects: 135
Study: 34097710

Group type: EXPERIMENTAL
Intervention: Caregivers' experiences and health service problems
Number of subjects: 4142

Group type: EXPERIMENTAL
Intervention: Health system limitations
Number of subjects: 4142

Group type: COMPARATOR
Intervention: Deployment of midwives
Number of subjects: 4142

Group type: EXPERIMENTAL
Intervention: Community engagement and health system transformation
Number of subjects: 4142
Study: 33960201

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (4000 IU/d)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Low-dose vitamin D3 (400 IU/d)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Vitamin D supplementation (both doses)
Number of subjects: 289
Study: 32569164

Group type: EXPERIMENTAL
Intervention: Integrated Chinese and Western medicine treatment group (Jiawei qianyang dan)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Western medicine treatment group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups after 1 year of follow-up
Number of subjects: 110
Study: 34686815

Group type: EXPERIMENTAL
Intervention: AssistDent AI software
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group without AI assistance
Number of subjects: 23
Study: 32317229

Group type: EXPERIMENTAL
Intervention: Nighttime hydrating eyelid gel (TDHA-AOX and HA), applied nightly to the upper and inner eyelids of the right eye for 2 weeks
Number of subjects: 62
Study: 32125880

Group type: EXPERIMENTAL
Intervention: IPC1talc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom-guided drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily drainage
Number of subjects: 0
Study: 35397250

Group type: EXPERIMENTAL
Intervention: Video intervention (four brief videos with Black/White female and male presenters)
Number of subjects: 1993

Group type: COMPARATOR
Intervention: Nonintervention control condition
Number of subjects: 1993
Study: 33876183

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention including guidance to increase vegetables, fruit, and grains.
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 48835
Study: 32301241

Group type: EXPERIMENTAL
Intervention: Home management
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hospital management
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Home management and hospital management
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hybrid approach (brief stay in hospital and early home management)
Number of subjects: 22
Study: 35235859

Group type: EXPERIMENTAL
Intervention: Resistance training + saffron (RS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saffron consumption (S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 35368792

Group type: EXPERIMENTAL
Intervention: Nephrology Immersion Classroom (mobile-friendly digital blackboard videos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual inpatient nephrology consult rotation (control group)
Number of subjects: 0
Study: 35537502

Group type: EXPERIMENTAL
Intervention: T2HIGH/T17LOW group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: T2LOW/T17HIGH group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Correlation with T2 gene expression
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cystatin SN (CST1) expression
Number of subjects: 70
Study: 34095302

Group type: EXPERIMENTAL
Intervention: Deep cervical flexor muscle training using pressure biofeedback
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 55
Study: 33363364

Group type: EXPERIMENTAL
Intervention: Behavioral Activation + Usual Care
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual Care Only
Number of subjects: 82
Study: 33755799

Group type: EXPERIMENTAL
Intervention: Tourniquet inflated throughout the procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tourniquet used only during skin incision and cementation
Number of subjects: 50
Study: 32975739

Group type: EXPERIMENTAL
Intervention: D‐Fe (1000 IU/day vitamin D3 plus 27 mg/day iron)
Number of subjects: 87

Group type: COMPARATOR
Intervention: D‐P (vitamin D3 plus placebo)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 87
Study: 35804451

Group type: EXPERIMENTAL
Intervention: Sesame oil (SO) 30g/day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sunflower oil (SFO) 30g/day for 12 weeks
Number of subjects: 60
Study: 34672230

Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (SDT) 3g 3 times daily for 3 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (SDT)
Number of subjects: 50
Study: 35230962

Group type: EXPERIMENTAL
Intervention: No-therapist, single-session, online intervention targeting perceived control over anxiety
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo intervention encouraging handwashing
Number of subjects: 522
Study: 33084533

Group type: EXPERIMENTAL
Intervention: Serum calprotectin (SCal) levels in OSA patients
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Neutrophil/lymphocyte ratio (NLR) values in OSA patients
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Serum calprotectin (SCal) levels in severe OSA patients
Number of subjects: 67
Study: 33827495

Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counselling (ILC) followed by nine sessions of MOVE-I
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard treatment (14 sessions of individual manual-based cognitive behavioral therapy and motivational interviewing (MOVE-I))
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Participants in the trial
Number of subjects: 137
Study: 35550827

Group type: EXPERIMENTAL
Intervention: Baseline family communication quality
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Treatment aimed at improving family communication
Number of subjects: 147
Study: 34147142

Group type: EXPERIMENTAL
Intervention: Imatinib (800 mg loading dose on day 0 followed by 400 mg daily on days 1-9)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 400
Study: 35984380

Group type: EXPERIMENTAL
Intervention: Nebulized Salbutamol (5 mg) with Magnesium Sulphate (95 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nebulized Salbutamol (5 mg) alone
Number of subjects: 90
Study: 34965881

Group type: COMPARATOR
Intervention: Implementation program for shared decision-making (SDM) including training for HCPs, individual coaching for physicians, patient activation intervention, patient information material/decision aids, revision of quality management documents, and reflection on multidisciplinary team meetings (MDTMs).
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Implementation program for shared decision-making (SDM).
Number of subjects: 2128
Study: 32310850

Group type: EXPERIMENTAL
Intervention: Intracoronary prourokinase
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 260
Study: 32598812

Group type: EXPERIMENTAL
Intervention: Enoxaparin followed by warfarin (1 mg/kg every 12 hours for 7 days, then warfarin to maintain INR 2.0-3.0)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rivaroxaban monotherapy (15 mg twice/day for 21 days, then 20 mg/day)
Number of subjects: 42
Study: 34962672

Group type: EXPERIMENTAL
Intervention: 930 mg choline/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: 480 mg choline/d
Number of subjects: 20
Study: 32372290

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10/25 mg
Number of subjects: 14919
Study: 36235736

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 3 × 400 mg per day for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 34030705

Group type: EXPERIMENTAL
Intervention: SMC + vitamin A alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMC + vitamin A + zinc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMC + vitamin A + Plumpy’Doz™
Number of subjects: 0
Study: 32386077

Group type: EXPERIMENTAL
Intervention: Customised Consumer Medicine Information (CMI) with usual care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 140
Study: 34332269

Group type: EXPERIMENTAL
Intervention: Virtual Reality rehabilitation system (VRRS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional cognitive rehabilitation
Number of subjects: 30
Study: 34009905

Group type: EXPERIMENTAL
Intervention: Rapid Cycle Deliberate Practice (RCDP)
Number of subjects: 24
Study: 34254405

Group type: EXPERIMENTAL
Intervention: Lanicemine (BHV-5500) 1.0 mg/ml (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 24
Study: 32088427

Group type: EXPERIMENTAL
Intervention: In-person weight loss group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Video conference weight loss group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Enhanced usual care weight loss group
Number of subjects: 150

Group type: COMPARATOR
Intervention: No attendance
Number of subjects: 150
Study: 35727762

Group type: EXPERIMENTAL
Intervention: Foundation Residency Program
Number of subjects: 33
Study: 33421648

Group type: EXPERIMENTAL
Intervention: Group Mindful Self-Compassion training (8-week program via videoconferencing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed-treatment waitlist control group
Number of subjects: 0
Study: 34762373

Group type: EXPERIMENTAL
Intervention: Moxibustion combined with basic treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional basic treatment (control group)
Number of subjects: 60
Study: 36333364

Group type: EXPERIMENTAL
Intervention: 0.15% hyaluronic acid (HA)
Number of subjects: 438

Group type: COMPARATOR
Intervention: 0.05% cyclosporine A (CsA)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: 0.15% hyaluronic acid (HA) plus 0.05% cyclosporine A (CsA)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine A (CsA) plus 0.5% carboxymethylcellulose (CMC)
Number of subjects: 438
Study: 35162706

Group type: COMPARATOR
Intervention: Zumba (ZG)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Football (FG)
Number of subjects: 107
Study: 35232805

Group type: EXPERIMENTAL
Intervention: Tanezumab administered subcutaneously every 8 weeks
Number of subjects: 4480
Study: 32600327

Group type: EXPERIMENTAL
Intervention: 40-min chewing trial
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 60-min chewing trial
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison between 40-min and 60-min chewing trials
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison between sexes
Number of subjects: 31
Study: 33724101

Group type: EXPERIMENTAL
Intervention: Educational cognitive behavioral therapy fatigue management group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study: 35435089

Group type: EXPERIMENTAL
Intervention: Capacitive and resistive electric transfer (CRET) therapy for 15 minutes on lower back
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham therapy for 15 minutes on lower back
Number of subjects: 30
Study: 34408741

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DE111®
Number of subjects: 11
Study: 33402278

Group type: EXPERIMENTAL
Intervention: Inspiron™ sirolimus‐eluting stent (SES)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Biomatrix™ Flex biolimus‐eluting stent (BES)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both SES and BES
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 170

Group type: COMPARATOR
Intervention: BES
Number of subjects: 170
Study: 32996349

Group type: EXPERIMENTAL
Intervention: WeChat-based intervention
Number of subjects: 164
Study: 35635717

Group type: EXPERIMENTAL
Intervention: SHR6390 150-mg tablet under high-fat conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: SHR6390 150-mg tablet under fasting conditions
Number of subjects: 24
Study: 32193541

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (tCS)
Number of subjects: 111
Study: 34216470

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cipargamin
Number of subjects: 186
Study: 33960445

Group type: EXPERIMENTAL
Intervention: Imepitoin (30 mg/kg BID)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 32281393

Group type: EXPERIMENTAL
Intervention: Major CIED infection
Number of subjects: 0
Study: 33601673

Group type: EXPERIMENTAL
Intervention: Escitalopram (Group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Duloxetine (Group B)
Number of subjects: 160
Study: 32358566

Group type: EXPERIMENTAL
Intervention: Splicing factor mutations (SRSF2, U2AF1, SF3B1)
Number of subjects: 2678

Group type: EXPERIMENTAL
Intervention: SRSF2(P95H) mutants
Number of subjects: 2678
Study: 35708140

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 35169373

Group type: EXPERIMENTAL
Intervention: Debridement, antibiotics, irrigation and retention of prosthesis (DAIR)
Number of subjects: 70
Study: 35700926

Group type: EXPERIMENTAL
Intervention: mHealth application
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study: 32149425

Group type: EXPERIMENTAL
Intervention: On-site active referral (OSR)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Mobile text messaging referral (TMR)
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Brief cessation advice only (control)
Number of subjects: 1163
Study: 32189052

Group type: EXPERIMENTAL
Intervention: Diagnostic tree analysis model based on ultrasonography and clinical findings
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: DTA model based on categorical parameters alone
Number of subjects: 242
Study: 33683799

Group type: EXPERIMENTAL
Intervention: IPAQ-SF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PASE
Number of subjects: 0
Study: 36027443

Group type: EXPERIMENTAL
Intervention: Dual SPC arm (perindopril/amlodipine) initial dose 4/5 mg, up titrated to 8/5 mg, 8/10 mg if needed.
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Triple SPC arm (perindopril/amlodipine/indapamide) initial dose 4/5/1.25 mg, up titrated to 8/5/2.5 mg, 8/10/2.5 mg if needed.
Number of subjects: 440
Study: 32572802

Group type: EXPERIMENTAL
Intervention: CoQ10 (200 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/day)
Number of subjects: 70
Study: 36162067

Group type: EXPERIMENTAL
Intervention: Group Support Psychotherapy (GSP)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Group HIV Education (GHE)
Number of subjects: 1140
Study: 34161706

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Azithromycin (1-g single dose)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 625

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 625
Study: 36456992

Group type: EXPERIMENTAL
Intervention: Vildagliptin treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33439221

Group type: EXPERIMENTAL
Intervention: Postdischarge video‐based virtual visit
Number of subjects: 432

Group type: COMPARATOR
Intervention: In-person follow-up
Number of subjects: 432
Study: 35798680

Group type: EXPERIMENTAL
Intervention: Internet-based behavioral activation (BA) intervention
Number of subjects: 127

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 127
Study: 33536003

Group type: EXPERIMENTAL
Intervention: Reduction strategy for tobacco use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of food insecurity reduction strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strategies addressing excess alcohol use and overcrowding
Number of subjects: 0
Study: 35471613

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 30
Study: 32394654

Group type: EXPERIMENTAL
Intervention: SHAO's five-needle method
Number of subjects: 210

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 210
Study: 33298706

Group type: EXPERIMENTAL
Intervention: The Coleman Care Transition Intervention adapted for ED visitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 0
Study: 32174482

Group type: EXPERIMENTAL
Intervention: Treadmill training with 16 anterior-posterior perturbations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treadmill walking (control group)
Number of subjects: 30
Study: 33557599

Group type: EXPERIMENTAL
Intervention: FOCUS (mHealth intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: WRAP (clinic-based intervention)
Number of subjects: 0
Study: 35011054

Group type: EXPERIMENTAL
Intervention: Nutritional protein supplementation (NS)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Nutrition education (NE)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combined nutritional protein supplementation and nutrition education (NS + NE)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual supportive care from ASHA (UC)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Usual supportive care from ASHA (UC) plus nutrition education (NE)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Usual supportive care from ASHA (UC) plus nutritional protein supplementation (NS)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combined UC plus NE plus NS
Number of subjects: 600
Study: 34134825

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)‐enhanced parent‐teen behavior therapy
Number of subjects: 114
Study: 33063705

Group type: EXPERIMENTAL
Intervention: Subcutaneous autologous serum therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional intramuscular autologous serum therapy
Number of subjects: 64